Linda Gail Bekker highlighted the critical importance of oral loading with lenacapavir. Missing it significantly delays (to 28 days) the time taken to achieve target concentrations which are reached by day 2 with loading #IAS2025 @iasociety.bsky.social

Next steps for lenacapavir PrEP #IAS2025 @iasociety.bsky.social

In our latest episode of The Future of HIV Care on TheBodyPro, @drlaurajwaters.bsky.social and I share what's on our minds about lenacapavir PrEP approval in the U.S., the growing concern about the future of U.S. HIV clinical guidelines, and... goats. www.thebodypro.com/podcast/hiv/...

Impact of PEPFAR cuts on HIV care in Mozambique #IAS2025 with 3rd highest no of PWH & 2nd highest new diagnoses, 67% of funding from PEPFAR in 2022. - 14% reduction in ART initiations - 39% increase in ART interruption - reduced VL testing & viral suppression, esp children @iasociety.bsky.social

#IAS2025 first ever lenacapavir PrEP implementation study will be in Brazil! Will include a mobile PrEP unit in Sao Paolo to best reach communities who will benefit @iasociety.bsky.social

At the IAS members meeting with a wondrous panel (see pic). I'm finding the discussions about funding & the struggles people experience trying to fund their attendance really emotive. This will be increasingly challenging in the future & I wish I had a solution #ias2025

The much anticipated DO-IT trial shows no impact of switch from TAF + INSTI to DOR (with TAF or TDF) on weight in people with obesity. Considering switching ART only to address weight change? DON'T DO-IT..... #IAS2025 @iasociety.bsky.social

The TECAIN Study (tricholoacetic acid vs electrocautery for AIN treatment in people with HIV) at 24W showed TCA non-inferior to ECA. #IAS2027 @iasociety.bsky.social @tristanjbarber.bsky.social

IMPALA results at #IAS2025 1 incident HBV infection in the CAB/RPV arm No evidence of HBV reactivation (note people with detectable cAb but sAb <10 were excluded) @iasociety.bsky.social @profchloeorkin.bsky.social @tristanjbarber.bsky.social

Rosemary Mburu #ias2025 "Science is not just data! It is DIGNITY. Investment in people is not just nice to have, it's creating powerful agents for change. RESILIENCE MUST BE MET WITH RESPECT @iasociety.bsky.social

Beatriz Grinszetjn Opens #ias2025! While she can't provide a recipe for success in current climate, there are key factors 1. EVIDENCE 2. SOLIDARITY 3. TRUTH Let us make the most of our time together at the conference to "reaffirm, refocus & rebuild!" @iasociety.bsky.social

New @who.int postnatal prophylaxis guidelines : Infants at ow-risk - preferred: 6W NVP for 6W - alternative: DTG or 3TC for 6W Infants at high-risk - ABC + 3TC + DTG for 6W - plus extended PNP during breastfeeding (nevirapine preferred, DTG or 3TC alternatives) #IAS2025 @iasociety.bsky.social

New World Health Organization guidelines recommend darunavir as preferred PI and new appearance for LA-CAB/RPV as a switch option for people who are virally suppressed. #IAS2027 @iasociety.bsky.social @who.int @tristanjbarber.bsky.social

@who.int guidelines launch at #IAS2025 includes the just released guidelines on LEN PrEP including recommendation to use HIV rapid tests, NAAT too slow & expensive.... iris.who.int/bitstream/ha... @tristanjbarber.bsky.social

Mitchell Warren of AVAC shares data, based on many assumptions, of potential injectable PrEP use in 2026 based on 2024 oral uptake & preference data. And the ways forward.....prioritise, prioritise, prioritise (sorry, I changed the spelling 😘) #IAS2025

We are at an absolutely critical point in the HIV response which is why the @iasociety.bsky.social conference in Kigali so so very important. And when LISTENING is more important than ever, the live translation feature for the main sessions is particularly welcome....well done IAS #IAS2025

📢 BASHH has today published national clinical guidelines on the use of doxyPEP. This makes the UK one of the first countries globally to offer formal clinical direction on this STI prevention strategy. 🔗 Read our full statement & access the guidelines: bit.ly/4475DDK

Outstanding presentation on gender affirming care for adults in the UK from Alison Berner #bashh2025 The 2 screenshots provide invaluable advice, & until new NHSE guidance is produced, the 2019 advice applies @bashhuk.bsky.social

What happens when you throw @paulsaxmd.bsky.social, @drlaurajwaters.bsky.social, Monica Gandhi, and David Wohl into a (virtual) room together and ask them to talk about anal cancer screening guidelines in HIV care? Weird question to ask, but I've got the answer. www.thebodypro.com/video/hiv/an...

Fast-Track Cities is a partnership working towards zero new #HIV infections, zero deaths and zero stigma before 2030. For #TeamTuesday meet Dr Laura Waters, HIV National Specialty Advisor and member of our leadership team https://fasttrackcities.london/team/laura-waters/ @drlaurajwaters.bsky.social

Volunteers wanted! , Are you a sexually active woman who might benefit from #PrEP ? @profygilleece.bsky.social @profchloeorkin.bsky.social @drlaurajwaters.bsky.social @drrageshri.bsky.social @savinglives.bsky.social www.bbc.co.uk/news/article...

The Birmingham AIDS & HIV Memorial Legacy Project 'Cover Up Quilts' are on display at #BHIVA25. Come & meet the Project Lead, Garry Jones and see several quilts made by people living with #HIV. This project was part funded by the @bhiva.bsky.social @drlaurajwaters.bsky.social community fund.

Huge congratulations to my dearest friend & colleague @tristanjbarber.bsky.social who will be the new @bhiva.bsky.social chair from November!!!! Wise & stylish shoes to fill but I'm sure @profygilleece.bsky.social is delighted it's your feet next 😘😘😘😘

Totally thrilled to be working with @drlaurajwaters.bsky.social and Dr. Magnus Gisslen again to summarize the top studies from #CROI2025. #IDSky #HIVSky Please sign up to join us! 31 March, 2025 medevents.se/events/ch2-2025

One observation from me during the hot new #HIV therapies session at #CROI2025. Others have been posting abt the data showing options for LA CAB/bNAb, ISL/DOR, and CAB/RPV in Africa but my hot take is: Look at the impressive % of women in these trials! 58% in CARES 21 & 40% in the ISL/DOR studies

The Gilead press release (scroll down to "landmark"): www.gilead.com/news/news-de...

@brendacrabtreer.bsky.social makes excellent point in excellent closing session on INSTI resistance. We should talk about 'INSTI resistance' not 'DTG resistance'. Some LMIC have bictegravir too you know....! And much INSTI resistance is due to prior exposure to 1st generation INSTI too.... #CROI2025

💯 this. We need to *lead* people! #CROI2025

FFFS. Maybe I'm just particularly grumpy & tired today but stop saying that PEOPLE FAILED. Their treatment failed. Especially when they are on injectables and had all their injections on time. I'm literally flinching each time I hear it. @peoplefirstcharter.bsky.social #CROI2025

Sobering talk from an excellent Jeremy Nel on global implications of INSTI resistance. "Nuisance for HIC but profound challenges for LMIC" - so true #CROI2025

It doesn't take much to make language person-first..... "those failing ART" - is it the person's fault?! "those on failing ART" - 'blames' the regimen not the person Small things, big impact #languagematters #CROI2025 www.peoplefirstcharter.org @peoplefirstcharter.bsky.social

Sorry ViiV but if you believe Q2M CAB as good as QM, why, when combining CAB with the bNAb N6LS, is it more cautious to use QM? We know there are numerically more VF on Q2M CAB/RPV than QM & this study design suggests you have more faith in that QM dose. Unless I missed something? #CROI2025

More daily DOR/ISL from @profchloeorkin.bsky.social #CROI2025 This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic. Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV

More daily DOR/ISL from @profchloeorkin.bsky.social #CROI2025 This time open-label, various ART - efficacy (incl 5 with viraemia on DOR/ISL) in pic. Weight gain on DOR/ISL driven by removal of weight suppressive TDF and/or EFV

#CROI2025 continued Biktarvy vs switch to daily ISL/DOR with ISL at safer lower dose of 0.25mg. ISL/DOR non-inferior at W48, 2 CVFs, no RAMs, both resuppressed in Biktarvy, no diff in CD4/TLC. 2 cases acute HBV in cAb- & sAb- people

Ph2b EMBRACE #CROI2025 Q4M N6LS + QM CAB bNAb SC vs IM vs continued oral in VS ppl. 4CVFs on N6LS/CAB, 1 with CAB RAMs, 3 with N6LS resistance. IV will be going forwards

96W CARES CAB/RPV. Efficacy remains high and non-inferior vs continued oral ART (97% <50) 4 VFs on LA (0 on PO) 3/4 with dual class RAMs (1 with baseline RPV RMAs) 1/4 not sequenced. Great results.

ACTG5418: Tecovirimat vs PBO clade 2 mpox n=344 #CROI2025 Study stopped early due to DSMB futility analysis (unbeknownst to study team?!) 25% recruited remotely HR for clinical resolution....0.98 (o.74-1.31) & no diff in subgroup analysis incl symptom duration. No difference in viral clearance/pain

#CROI2025 19-43% C19 household transmission rates. SCORPIO randomised >2300 contacts to ensitrelvir vs PBO (78% enrolled within 48h of symptom onset in index case, 37% of whom were at high risk of complications. 67% reduction in C19 acquisition 1 at day 10!! 76% if high risk! WOW.

Letermovir (CMV terminase inhibitor) does some good stugg. Delightfully passionate conclusion!! #CROI2025

What is it with the facile images representing mortality at #CROI2025?! After the grim reaper earlier today, now we have a gravestone. Do we really need these pictures, especially when they are so starkly associated with the early years of the HIV epidemic. REALLY?!?!?

#CROI2025 semaglutide stablises biological ageing in people with HIV.

Can epigenetic clocks predict clinical events? Some so, some don't. GrimAge did best - but what a name! You can do your own for just $325....?! myagingtests.com/product/epig... #CROI2025

More from REPRIEVE #CROI2025. Frailty prognostic for MACE HR 1.76/2.14 for pre-frail/frail vs non-frail) No impact of frailty on pitavastain effect though event number & sample size in group with frailty small.

Link to paper Steve Grinspoon mentioned at #CROI2025. Conclusion: PCE risk score underpredicted cardiovascular events in women & Black or African American men in high-income countries and overpredicted cardiovascular events in low-income and &-income countries. www.thelancet.com/journals/lan...

REPRIEVE #CROI2025 - relating entry risk factors to MACE. Some trad (age/ASCVD risk) + non-trad risk factors (hsCRP/IL-6/non-calcified plaque) more common in ppl with MACE. LDL slightly LOWER?! Non-calcified plaque predictive of MACE (8% vs 3% in ppl without plaque).Lower CRP on statin.

Scant data on CAD in ppl with HIV in Africa. Lower rates of coronary artery disease in Uganda than other cohorts & smaller difference between people with/without HIV #CROI2025 We can't extrapolate US data to other regions - study the populations affected to inform public health interventions

Remember START?! #CROI2025 CVD with extended FU, rates pre/post unblinding. No difference between groups randomised to immediate vs deferred ART. Caveats: young age, low event rate

Really?! Maybe it's just me? #CROI2025

Link to Rebecca Denison's INCREDIBLE #CROI2025 plenary here. A must watch lnkd.in/e76i2nTV @bhiva.bsky.social @iasociety.bsky.social @eacsociety.bsky.social @thelancet.bsky.social @nejm.org @thtorguk.bsky.social @bashhuk.bsky.social @profchloeorkin.bsky.social @tristanjbarber.bsky.social